Entresto (Sacubitril and Valsartan) is a NEW approved medication used to treat chronic heart failure (HFrEF, or HF) in certain patients. Entresto belongs to the new drug classed called angiotensin II receptor blocker neprilysin inhibitors (ARNIs). It is a combination of two medications. One is sacubitril, which is a neprilysin inhibitor. The second is valsartan (Diovan), which is an angiotensin II receptor blocker. They work by lowering blood pressure and improving blood flow. It is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. A valid prescription is required to purchasing Entresto. Other prescription heart medications include Altace, Aldactone, and Coreg.
Entresto (Sacubitril/Valsartan): first-in-class angiotensin receptor neprilysin inhibitor FDA approved for patients with heart failure (American Health & Drug Benefits, September 2015) - Loretta Fala, found that "sacubitril plus valsartan reduced the risk for death from CV causes by 20%, reduced the risk for hospitalization for heart failure by 21%, and reduced heart failure–related symptoms and physical limitations compared with enalapril."
Manufacturer Information
We currently have the brand Entresto comes from Canada, Australia, and India (also known as Vymada) manufactured by Novartis. Entresto is supplied as unscored, ovaloid, film-coated tablets in several dosages and strengths:
• 24 mg/26 mg (available in quantities of 56, 84, 168 tablets, from Australia and India)
• 24.3 mg/25.7 mg (available in quantities of 30 and 90 tablets, from Canada)
• 48.6 mg/51.4 mg (available in quantities of 60 and 180 tablets, from Canada)
• 97 mg/103 mg (available in quantities of 84 tablets, from India)
• 97.2 mg/102.8 mg (available in quantities of 60 and 180 tablets, from Canada)
Generic Entresto comes from India manufactured by Cipla, also it is known as Azmarda. It comes in the strength of 24 mg/26 mg 84 tablets.